Hundreds of people report pancreas problems linked to weight loss jabs
Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects.
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal.
Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.
This includes:
– 181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died.
– 116 reported reactions of this kind linked to liraglutide, one of which was fatal.
– 113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy. One person died.
– 101 reported reactions of this kind linked to exenatide, three people died.
– 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug.
These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be.
Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup.
The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme.
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study.
Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes.
GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss.
Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs.
Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.
Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea.
And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients.
Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone.
'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup.
'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme.
'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.'
Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects.
'We believe there is real potential to minimise these with many adverse reactions having a genetic cause.
'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Get all the latest news from around the country Follow STV News
Scan the QR code on your mobile device for all the latest news from around the country
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
23 minutes ago
- Sky News
Why weight loss jabs might not be a wonder drug
👉 Listen to Sky News Daily on your podcast app 👈 Recent years have seen the advent of weight loss drugs, including Ozempic and Wegovy. They work by suppressing users' appetites, leading to weight loss. They've been described as wonder drugs but now, new figures from the Medicines and Healthcare products Regulatory Agency (MHRA) show they may be associated with inflammation of the pancreas, which could lead to death. Niall Paterson speaks to Sky's science correspondent Thomas Moore about these new findings and how cautious they should make us. We also hear from Lorna, a mother who got acute pancreatitis while she was on a weight loss drug - she believes the drugs are not worth the risks.
Scottish Sun
3 hours ago
- Scottish Sun
I lost 11st thanks to Mounjaro but hate my apron belly & saggy boobs – I need strangers to help me pay for op to fix it
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A MUM who lost 11st with the help of Mounjaro says she "struggles to look at herself naked" after she was left with saggy skin. Jade Stalker, 36, weighed 22st 8lbs at her heaviest, after decades of scoffing crisps, Chinese takeaways and piled-high plates of spaghetti Bolognese. Sign up for Scottish Sun newsletter Sign up 4 Jade Stalker shed an incredible 11st with help from Mounjaro Credit: SWNS 4 But mum Jade has been left with saggy skin that she hates Credit: SWNS 4 She tipped the scales at 22st 8lbs at her heaviest Credit: SWNS 4 Jade has launched an online fundraiser so she can have the excess skin surgically removed Credit: SWNS Just before her daughter, now five, started nursery in May 2023, Jade was concerned she'd be seen as one of the "fat mums" at the school gates - and made a bid to lose 10st. After splashing out £3,500 on flights to Turkey and gastric sleeve surgery, and starting Mounjaro, Jade dropped nearly 30in from her waist and feels "fantastic." But she admits there has been a major drawback when it comes to her weight loss. Now 11st 8lbs, she says she's been left with an "overhang on her stomach" and "saggy" boobs due to excess skin, and added: "The loose skin makes me depressed and I struggle to look at myself naked sometimes." She has launched on online fundraising page to raise £6,000 for surgery to remove excess asking from her stomach, breasts and inner thighs. Jade, a telecommunications engineer from Sauchie, Scotland, said: "My skin now is so loose, when I get in the bath, it ripples. "I have quite a large overhang on my stomach - and my boobs are saggy, despite my doctors telling me they'd get smaller after losing all the weight. "My partner loves me the way I am - she doesn't care about all that - but I think when you're in a relationship, you do want to look good for your partner." Jade, who wears men's clothes and started at a 58in waist, says she's never been bothered about her size. She'd have four ham rolls for breakfast, two bags of crisps as a snack, a Tesco meal deal for lunch and a "man-size" plate of spaghetti Bolognese with garlic bread for dinner. I'm so happy with my Mounjaro body after dropping 4 stone but there's a side effect I hate & trolls say I 'cheated' But becoming a mum changed her view. Wanting to teach her daughter "what a healthy body looks like" she booked flights and a gastric sleeve operation in Turkey, in May 2023. She could barely eat three-quarters of a burger, after the surgery and lost 5st 8lb in a year. But she said the operation hadn't done enough to cure her "head hunger," so began a course of Mounjaro via an online pharmacy in October 2024. "The only thing that made me less mentally hungry was Mounjaro," she said. "Being on it is like walking through Tesco when you've just had a huge meal." Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. About half a million Brits use weight loss drugs - and the number is expected to double in the next year. Mounjaro works by suppressing your appetite, making people feel fuller for longer. The injections are licensed for patients with type 2 diabetes and to assist those who are clinically obese (with a Body Mass Index of 30 or over). One jab is administered each week but the duration is dependent on someone's weight. Jade lost a further 5st 2lb thanks to the jabs. She noticed "saggy skin" early into her weight loss journey but initially thought it was "fat" she "still had to lose". She added: "I'd say my most conscious areas are my stomach, my boobs and my inner thighs - although I'm quite a tomboy so I wear long trousers most of the time. "I've held off from doing a GoFundMe, but it's getting to the point where it's bothering me so much - even if one or two people could donate, it would be a huge help."
Daily Mail
4 hours ago
- Daily Mail
Revealed: Shocking number of deaths linked to weight loss jabs...as health chiefs issue chilling alert about organ-destroying side effect
More than 100 deaths in Britain have now been linked to blockbuster weight loss jabs, official data shows. Two of the victims were people in their 20s, according to a MailOnline analysis of logs kept by the medicine safety watchdog. Of the 107 fatalities reported by doctors and patients, the vast majority involve slimming jabs approved within the last few years, such as Mounjaro and Ozempic. The findings come as the Medicines and Healthcare Products Regulatory Agency (MHRA)confirmed that at least 10 people in the UK using the injections had died from pancreatitis; a life-threatening inflammation of the pancreas. Officials announced last night that they are now investigating if the condition is more likely to strike some patients with specific genes. It comes just months after the death of 58 year-old Scottish nurse Susan McGowan who suffered multiple organ failure, septic shock and pancreatitis after just two doses of Mounjaro—the so-called 'King Kong' of weight loss jabs. Ms McGowan is currently the only named fatality linked to the jabs in the UK. However, medics have told of a wave young women requiring life-saving A&E treatment after obtaining the drugs privately from online pharmacies. In the majority of these cases, the victims had no weight-related health problems but were using the drugs for cosmetic reasons. Some were not even overweight. Of the 107 deaths recorded by the MHRA the majority were linked to a weight-loss jab called liraglutide, with 37 fatalities since 2010. This drug—sold under the brand Saxenda—works similar to the more famous brands Wegovy and Mounjaro and is approved as a weight loss drug in the UK. The vast majority of fatalities linked to the drug were among the over 50s, though two were recorded in patients in their 20s. Semaglutide—the active ingredient in Ozempic and Wegovy—and tirzepatide, sold as Mounjaro, had an equal number of linked fatalities with 30 apiece. However, Mounjaro has reached this total much faster, with 30 reports linking it to deaths in just a year-and-half. Semaglutide has taken five-and-half-years to reach this number of linked fatalities. Mounjaro has been dubbed the 'King Kong' of weight loss jabs due to its potency, helping people lose up to a fifth of their body weight in a year. Twelve other deaths were recorded for similar drugs—collectively known as 'GLP-1' injections—but which are approved solely for use in treating diabetes. Weight loss injections work by mimicking natural appetite suppressing hormones to make people feel fuller, helping them lose weight. All deaths were logged under the Medicines and Healthcare products Regulatory Agency (MHRA) 'Yellow Card' scheme. The system—set-up in the wake of the 1960s thalidomide scandal—allows officials to track potential adverse reactions to medications approved for use in the UK and spot emerging patterns. Every drug approved for us in the UK has to go through safety trials before being made available to the public. But there is an unavoidable risk that rare reactions or interactions with other illnesses and conditions may have been missed, which is where the Yellow Card system comes in. If a worrying pattern emerges it can lead to drugs' approval being reviewed, having new warnings added to the labels or the medication potentially being taken off the market completely. As anyone can use the system—patients as well as their medics—a death being linked to a specific drug is not proof it was responsible. The MHRA highlights that some reactions—including fatal ones—may simply be coincidence. For example, a patient taking a weight loss jab may experience a fatal heart attack, but the event may have nothing to do with the drug they were taking at the time. Last night the MHRA said it had received more than 560 reports of patients developing an inflamed pancreas from taking GLP-1 injections since they first launched. While these drugs are frequently used for weight management, some like Ozempic are primarily licensed for the treatment of type 2 diabetes. Of the 10 linked pancreatitis fatalities, five were connected to Mounjaro. Scientists aren't completely clear on why GLP-1 drugs can trigger deadly pancreatitis. However, experts suspect the reaction is caused by how the drugs interact with the pancreas by triggering it to release the hormone insulin, helping to stabilise blood sugars. Scientists say in some cases this may 'overstimulate' cells in the organ—putting excess strain on it—and causing the pancreas to become severely inflamed. The MHRA is now calling for users who are admitted to hospital with pancreatitis to report the side effect to authorities using the regulator's Yellow Card scheme. Healthcare workers can also submit a report on patients' behalf. Such patients will then be contacted by the MHRA to ask them to take part in a new study, to see if they have a gene that makes them at higher risk of pancreatitis while taking the drugs. The ultimate aim is to create a test that will enable medics to find if a patient has these pancreatitis-risk genes before they prescribe the drugs. Patient safety leaflets distributed with Ozempic, Wegovy, Mounjaro and Saxenda all acknowledge pancreatitis as a potential rare reaction to taking the drug. The main symptom of pancreatitis is severe pain in the stomach that radiates to the back and does not go away. Anyone who experiences this should seek immediate medical help. Ms McGowan—the only named fatality from using weight loss jabs in the UK—took Mounjaro, for a two-week period before her death on September 4 last year. Just days after taking the drug, she started having severe stomach pains and went to A&E at the hospital she worked at, University Hospital Monklands in Airdrie, Scotland. Although her colleagues fought to save her, she died shortly after. Her death certificate listed multiple organ failure, septic shock and pancreatitis as the immediate cause of death but added the prescribed use of tirzepatide as a factor. The MHRA's announcement comes a day after experts issued guidance to GPs to look for two life-threatening conditions that can be triggered by weight loss jabs acute pancreatitis and biliary disease. The advice tells doctors to look for signs of two life-threatening conditions that can be triggered by the drugs—acute pancreatitis and biliary disease. Warnings over the potential side effects of taking weight-loss jabs come just as the Government makes it easier for Britons to take them. From this week patients in England this week will be able Mounjaro, through their family doctor for the first time. The weekly injection will be offered to around 220,000 people over the next three years under the new NHS prescribing rules. Under previous regulations patients could only access Mounjaro on the NHS via a limited number of specialist weight loss clinics ran by the health service. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs, many of which are bought privately due to NHS rationing. Health officials have suggested that they can help to turn the tide on obesity but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. However, the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. A spokesperson for Lilly UK, the makers of Mounjaro, reacting to reports of deaths linked to the drug said patient safety is its 'top priority'. They added: 'Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine and Lilly is committed to continually monitoring, evaluating, and reporting safety data.' 'If anyone is experiencing side effects when taking any Lilly medicine, they should talk to their doctor or other healthcare professional.' In the US, nearly 200 deaths have been linked to weight loss jabs.
